WEST LEBANON, N.H., Oct. 29, 2014 /PRNewswire/ -- Novo Nordisk, a global pharmaceutical company that produces medicines for patients with diabetes, hemophilia or growth-related disorders, announced plans to hire up to 90 people at its newly-acquired manufacturing plant in West Lebanon, NH. The facility was formerly owned by Olympus Biotech.
The facility will produce products for the treatment of hemophilia in the United States, including the long-acting recombinant factor VIII, N8-GP for those with hemophilia A.
"We're pleased to be bringing this site back to life, and make it a part of Novo Nordisk's growing network of manufacturing sites," said Steen Weber Jensen, corporate vice president, Novo Nordisk. "Our long-standing commitment to patients and families affected by hemophilia means we have to continuously improve how we supply our medicines, and this new site will give us new, vital capacity."
"Novo Nordisk is making a long-term investment in the Upper Valley, and we're glad that New Hampshire is a part of the company's manufacturing division," added Peter Gariepy, vice president and site manager for the West Lebanon plant. "The community can look to Novo Nordisk to be a cornerstone for the foreseeable future."
Those looking to apply for opportunities at the New Hampshire plant can visit www.novonordisknewhampshirejobs.com for more information and details about positions.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk-US.com or follow us on Twitter @NovoNordiskUS.
SOURCE Novo Nordisk